Latest news
Chapel Hill drug developer's stock plunges 90% after trial setback - The Business JournalsThe Business Journals · Mon, 10 Aug 2026 19:48:00 GMTTenax's oral levosimendan misses primary endpoint in Phase 3 LEVEL PH-HFpEF trial - DealroomDealroom · Mon, 10 Aug 2026 16:55:56 GMTTenax’s levosimendan fails Phase III LEVEL trial in PH-HFpEF - AllSciAllSci · Mon, 10 Aug 2026 16:40:47 GMTTenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 15:03:31 GMTTNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLiveHCPLive · Mon, 10 Aug 2026 15:03:24 GMTWhy Did TENX Stock Crash 89% Today? - TradingViewTradingView · Mon, 10 Aug 2026 14:23:30 GMTSionna Therapeutics shares collapse 92% after cystic fibrosis trial misses key endpoint - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 12:48:07 GMTTenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint - TradingViewTradingView · Mon, 10 Aug 2026 11:09:24 GMT